EU Mission on Cancer Reaches Five-Year Mark: Progress Toward Target of Improving 3 Million Lives by 2030
The EU Mission on Cancer, launched in 2021 as part of the Horizon Europe missions framework, reached its five-year milestone in 2026, with the European Commission publishing a comprehensive progress report on the trajectory toward its central objective: improving the lives of 3 million people by 2030 through prevention, earlier and more accurate diagnosis, more effective treatments, and patient-centric quality of life. The Mission is one of five EU Missions defined under Horizon Europe, alongside Climate Adaptation, Soil Health, Smart Cities and Ocean.
The five-year results
The Commission report identifies concrete advances across four pillars. First, prevention: support for member states to deliver tobacco and alcohol harm-reduction policies, integration of HPV vaccination programmes, and promotion of cervical and colorectal screening at scale. Second, early diagnosis: roll-out of new low-dose lung cancer screening pilot programmes in 17 member states, AI-supported breast cancer screening tools deployed across 10 countries. Third, treatment innovation: dedicated funding for next-generation oncology research including CAR-T therapies, multi-omic profiling and precision oncology. Fourth, quality of life: development of survivorship care pathways and integrated palliative-care frameworks.
UNCAN.eu and data infrastructure
The Mission has catalysed the UNCAN.eu initiative, an unprecedented EU-wide effort to understand cancer by integrating molecular, clinical and lifestyle data across millions of patients. The initiative builds a federated research infrastructure compatible with GDPR, allowing researchers to interrogate harmonised datasets without centralising patient data. Twelve national hubs are operational by mid-2026, with ten more under preparation. Combined with the European Health Data Space, UNCAN.eu represents a structural transformation of cancer research capacity in Europe.
The European Cancer Patient Digital Centre
A flagship of the Mission’s patient-centric pillar is the European Cancer Patient Digital Centre, a multilingual platform offering personalised information, peer support, navigation guidance and access to clinical trials across the EU. As of May 2026, the platform is operational in 14 languages, with planned expansion to all 24 official EU languages by 2027. Patient engagement is central: more than 200 patient associations and individual patient experts are involved in governance and content curation.
Equity and inequalities
The progress report frankly acknowledges that major inequalities persist across the EU. Cancer mortality rates in Eastern and Southern member states remain significantly higher than the EU average, due to later diagnosis, less access to innovative therapies, and weaker survivorship support. The Mission has prioritised cohesion-oriented projects in Romania, Bulgaria, Hungary, Poland, Latvia, Lithuania, Greece and Portugal, with EU funding earmarked specifically for capacity-building in cancer care infrastructure.
The role of patients, researchers, charities
The Mission’s governance model rests on a broad coalition: researchers, innovators, patients, medical professionals, charities, funders, and policymakers. “Your expertise, experience, and voice are essential to make this transformation possible,” the Mission’s lead board emphasises in its 2026 message. Major charities including Europa Donna, the European Cancer Organisation, Childhood Cancer International Europe, and the European CanCer Organisation are formal partners.
Toward 2030
The next four years will determine whether the Mission delivers on its 2030 targets. Critical priorities include: scaling AI-supported screening, accelerating clinical trial harmonisation, deploying personalised oncology at scale, addressing the workforce gap in oncology nursing and palliative care, and translating UNCAN.eu’s data infrastructure into real-world treatment decisions. Stella Kyriakides, the former Commissioner who launched the Mission, has called the next four years “the moment of truth” for European cancer policy.
